Complementary and alternative medicine in multiple sclerosis

Moawad, Heidi; Shepard, Katie M.; Satya‐Murti, Saty

doi:10.1212/cpj.0000000000000020

Cited by 4 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PwMS often have symptom management regimens and may also take herbal and other supplements. 21 , 22 Thus, the possibility of pharmacologic interactions is high. 23 CBD and THC affect common targets for drug metabolism (such as cytochrome P450 [CYP]3A4/2C19 enzymes), which may affect the pharmacokinetics/pharmacodynamics of other drugs that interact with these pathways.…”

Section: Discussionmentioning

confidence: 99%

Sources of Cannabis Information and Medical Guidance for Neurologic Use

et al. 2022

View full text Add to dashboard Cite

Objective:As cannabis products become increasingly accessible across the United States, understanding how patients obtain medical information on cannabis and view the role of their healthcare provider in providing information is important.Methods:Participants with multiple sclerosis (MS) from the North American Research Committee on Multiple Sclerosis (NARCOMS) registry completed a supplemental survey on Δ9-tetrahydrocannabinol-containing cannabis use between March and April 2020. Participants reported dialogue with healthcare providers regarding cannabis use, information sources used to make product decisions, and expenditure on cannabis. Findings are reported using descriptive statistics.Results:Overall, 3249 participants responded (47% response rate) of whom 31% ever used cannabis and 20% currently used cannabis for MS. To determine presumed cannabis contents, respondents who had ever used cannabis (ever users) most often used dispensary-provided information (39%), word of mouth/dealer/friend (29%), and unregulated product labels (24%). For general information on cannabis for MS, ever users most often used dispensary staff (38%) and friends (32%). The primary source of medical guidance among ever users was most often ‘nobody or myself’ (48%) followed by a dispensary professional (21%); only 12% relied on their MS physician, although 70% had discussed cannabis with their MS physician. Most current users (62%) typically sourced their cannabis from a dispensary. The most common factor in selecting a cannabis product was perceived quality and safety (70%).Conclusions:Participants most often received information on cannabis for MS from dispensaries, unregulated product labels, and friends; only a small proportion used healthcare providers. Evidence-based patient and physician education is needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Sources of Cannabis Information and Medical Guidance for Neurologic Use

et al. 2022

View full text Add to dashboard Cite

show abstract

Shiatsu-associated physical therapy on pain and fatigue on people with multiple sclerosis

Fillis

Nicio

et al. 2022

Fisioter. mov.

View full text Add to dashboard Cite

Introduction: Pain and fatigue are common symptoms in multiple sclerosis (MS). Shiatsu, a technique that uses the pressure of fingers, associated with manual therapy, exercises and stretching can be used to control these symptoms. Objective: To evaluate the effect of Shiatsu associated with physical therapy on pain and fatigue on people with MS. Methods: Randomized clinical trial with people diagnosed with MS divided into two groups: intervention group (IG) - Shiatsu-associated physical therapy (n = 9), and control group (CG, n = 8). Participants were assessed before and after treatment by the Expanded Disability Status Scale (EDSS), Neuropathic Pain Questionnaire (DN4), Visual Analog Scale (VAS) and Fatigue Impact Scale (MFIS), and description of sociodemographic. Results: Seventeen people with MS (9 men) aged 45.18 ± 3.06 years participated in this study. In the total sample, the average of DN4 was 1.65 ± 20.02, VAS was 2.29 ± 2.80, MFIS was 39.47 ± 29.67, and 52.9 % had a score > 38 in the MFIS that corresponds to presence of fatigue. The values pre/post-intervention/grade of p, respectively in the IG were DN4: 2.78 ± 2.16/2.0 ± 2.12/0.432, EVA: 3.22 ± 3.27/0.33 ± 1.00/0.023, total MFIS: 44.44 ± 35.91/35 ± 31.70/0.068. In the CG the values were DN4 : 0.38 ± 0.744/2.25 ± 2.71/0.054, EVA : 1.25 ± 1.83/3.63 ± 2.38/0.043, and MFIS : 33.88 ± 21.68/25.13 ± 24.22/0.379. Conclusion: Shiatsu associated with Physiotherapy was effective in improving pain and fatigue in individuals with MS.

show abstract

Phytochemicals as inhibitors of tumor necrosis factor alpha and neuroinflammatory responses in neurodegenerative diseases

et al. 2022

View full text Add to dashboard Cite

Inflammatory processes and proinflammatory cytokines have a key role in the cellular processes of neurodegenerative diseases and are linked to the pathogenesis of functional and mental health disorders. Tumor necrosis factor alpha has been reported to play a major role in the central nervous system in Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis and many other neurodegenerative diseases. Therefore, a potent proinflammatory/proapoptotic tumor necrosis factor alpha could be a strong candidate for targeted therapy. Plant derivatives have now become promising candidates as therapeutic agents because of their antioxidant and chemical characteristics, and anti-inflammatory features. Recently, phytochemicals including flavonoids, terpenoids, alkaloids, and lignans have generated interest as tumor necrosis factor alpha inhibitor candidates for a number of diseases involving inflammation within the nervous system. In this review, we discuss how phytochemicals as tumor necrosis factor alpha inhibitors are a therapeutic strategy targeting neurodegeneration.

show abstract

Complementary and alternative medicine in multiple sclerosis

Cited by 4 publications

References 12 publications

Sources of Cannabis Information and Medical Guidance for Neurologic Use

Sources of Cannabis Information and Medical Guidance for Neurologic Use

Shiatsu-associated physical therapy on pain and fatigue on people with multiple sclerosis

Phytochemicals as inhibitors of tumor necrosis factor alpha and neuroinflammatory responses in neurodegenerative diseases

Contact Info

Product

Resources

About